• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Upexi Inc.

    7/29/25 2:25:29 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $UPXI alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001775194
    GROVE, INC.
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    UPEXI, INC.
    Jurisdiction of Incorporation/Organization
    NEVADA
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    UPEXI, INC.
    Street Address 1 Street Address 2
    3030 N. Rocky Point Drive Suite 420
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    Tampa FLORIDA 33607 727-287-2800

    3. Related Persons

    Last Name First Name Middle Name
    MARSHALL ALLAN
    Street Address 1 Street Address 2
    3030 N. Rocky Point Drive Suite 240
    City State/Province/Country ZIP/PostalCode
    Tampa FLORIDA 33607
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    President and Chief Executive Officer
    Last Name First Name Middle Name
    NORSTRUD ANDREW J
    Street Address 1 Street Address 2
    3030 N. Rocky Point Drive Suite 240
    City State/Province/Country ZIP/PostalCode
    Tampa FLORIDA 33607
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):

    Chief Financial Officer
    Last Name First Name Middle Name
    SALKIND GENE
    Street Address 1 Street Address 2
    3030 N. Rocky Point Drive Suite 240
    City State/Province/Country ZIP/PostalCode
    Tampa FLORIDA 33607
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    WILLIAMS THOMAS C
    Street Address 1 Street Address 2
    3030 N. Rocky Point Drive Suite 240
    City State/Province/Country ZIP/PostalCode
    Tampa FLORIDA 33607
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    DUGAN LAURENCE H.
    Street Address 1 Street Address 2
    3030 N. Rocky Point Drive Suite 240
    City State/Province/Country ZIP/PostalCode
    Tampa FLORIDA 33607
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
       Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
    X
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2025-07-11    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
       Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
       Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number X None
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    Street Address 1 Street Address 2
    City State/Province/Country ZIP/Postal Code
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $200,000,000 USD
    or    Indefinite
    Total Amount Sold $200,000,000 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    0
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    1

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $2,500,000 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Plus $150,000 in expenses.

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    UPEXI, INC. /s/ Andrew Norstrud Andrew Norstrud Chief Financial Officer 2025-07-29

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $UPXI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UPXI

    DatePrice TargetRatingAnalyst
    8/4/2025$15.00Buy
    Alliance Global Partners
    6/16/2025$16.00Neutral → Overweight
    Cantor Fitzgerald
    More analyst ratings

    $UPXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Salkind Gene bought $100,000 worth of shares (20,243 units at $4.94) and was granted 200,000 shares, increasing direct ownership by 60% to 585,370 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/30/25 4:47:19 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Dugan Lawrence bought $97,770 worth of shares (16,000 units at $6.11) and was granted 100,000 shares, increasing direct ownership by 29,820% to 116,389 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:05:17 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Marshall Allan bought $799,998 worth of shares (161,943 units at $4.94) and was granted 1,200,000 shares, increasing direct ownership by 154% to 2,246,261 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:03:08 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Upexi Establishes Advisory Committee and Welcomes Arthur Hayes as First Member

    Additional members to join the Advisory Committee in the coming weeks to optimize performance, increase visibility and unlock capital raising opportunities Arthur brings deep expertise, exposure and connectivity to both digital assets and traditional finance TAMPA, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the establishment of the Upexi Advisory Committee, composed of highly prominent individuals from the digital assets and traditional finance industries. Upexi will seek t

    8/12/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Surpasses 2 Million SOL in its Treasury

    TAMPA, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today released its periodic update. "July was a game-changing month for Upexi, particularly with respect to accretive capital raises and a resulting drastic increase in our Solana treasury," stated Allan Marshall, Upexi's Chief Executive Officer. "During the month, we raised over $200 million and grew our Solana holdings by over 172% to 2 million SOL. And we continued to generate additional value fo

    8/5/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference on August 12th-14th

    TAMPA, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced that management will participate in a fireside chat moderated by Joseph Vafi, Managing Director of Equity Research at Canaccord Genuity LLC, on Wednesday, August 13th at 1:30 p.m. ET at the Canaccord Genuity 45th Annual Growth Conference taking place at the InterContinental in Boston, MA. Presentation details, including a link to the live webcast, can be found below. Canaccord Genuity Conference:Dates: August 12-14, 2025Loc

    7/30/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on Upexi, Inc. with a new price target

    Alliance Global Partners initiated coverage of Upexi, Inc. with a rating of Buy and set a new price target of $15.00

    8/4/25 8:09:26 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi, Inc. upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded Upexi, Inc. from Neutral to Overweight and set a new price target of $16.00

    6/16/25 7:42:40 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Salkind Gene bought $100,000 worth of shares (20,243 units at $4.94) and was granted 200,000 shares, increasing direct ownership by 60% to 585,370 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/30/25 4:47:19 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    CSO Rudick Brian Benjamin was granted 400,000 shares, increasing direct ownership by 91% to 838,597 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:09:34 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Dugan Lawrence bought $97,770 worth of shares (16,000 units at $6.11) and was granted 100,000 shares, increasing direct ownership by 29,820% to 116,389 units (SEC Form 4)

    4 - UPEXI, INC. (0001775194) (Issuer)

    7/24/25 4:05:17 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    SEC Filings

    View All

    Upexi Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - UPEXI, INC. (0001775194) (Filer)

    8/20/25 5:00:44 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - UPEXI, INC. (0001775194) (Filer)

    8/15/25 5:00:34 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form S-1 filed by Upexi Inc.

    S-1 - UPEXI, INC. (0001775194) (Filer)

    8/11/25 7:30:24 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Leadership Updates

    Live Leadership Updates

    View All

    Upexi Establishes Advisory Committee and Welcomes Arthur Hayes as First Member

    Additional members to join the Advisory Committee in the coming weeks to optimize performance, increase visibility and unlock capital raising opportunities Arthur brings deep expertise, exposure and connectivity to both digital assets and traditional finance TAMPA, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the establishment of the Upexi Advisory Committee, composed of highly prominent individuals from the digital assets and traditional finance industries. Upexi will seek t

    8/12/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Financials

    Live finance-specific insights

    View All

    Upexi Purchases 83,000 SOL, Grows Treasury to 1.9 Million SOL Worth $381 Million

    TAMPA, Fla., July 23, 2025 (GLOBE NEWSWIRE) -- Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the acquisition of 83,000 SOL for $16.7 million, or $201.34 per SOL. The purchase brings the Company's holdings to 1.9 million SOL worth over $381 million using the $200.60 spot price of Solana as of 5:00 pm ET yesterday. Allan Marshall, Chief Executive Officer of Upexi, remarked, "The U.S. continues to make progress around digital asset legislation, which has the potential to usher in mass adoption of blockchain technology.

    7/23/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Grows Treasury to 1.819 Million SOL Worth $331 Million with a $58 Million Unrealized Gain in Under Three Months

    Upexi purchased an additional 100,000 SOL, and anticipates it may generate up to approximately $26 million in annual staking revenue based on current SOL holdingsCompany releases adjusted metrics for enhanced transparency and analysis TAMPA, Fla., July 21, 2025 (GLOBE NEWSWIRE) --  Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space, today announced the acquisition of 100,000 SOL, bringing its treasury holdings to 1,818,809 SOL worth $331 million. The recent purchase follows the successful closing of a roughly $200 million equity and c

    7/21/25 8:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    Upexi Regains Compliance with NASDAQ

    Filing Form 10-K for the Year Ended June 30, 2024Filing Form 10-Q for the Quarter Ending September 30, 2024 TAMPA, FL / ACCESSWIRE / December 23, 2024 / Upexi, Inc. (NASDAQ:UPXI) (the "Company" or "Upexi"), a brand owner specializing in the development, manufacturing and distribution of consumer products, announced its financial results for the year ended June 30, 2024 and the first quarter ending September 30, 2024 last week. On November 20, 2024 the Company received written notice (the "Compliance Notice") from Nasdaq informing the Company that it has regained compliance with Nasdaq Listing Rule 5250( c)(1) (the "Rule"). The Staff had concluded that with the filing of these two periodic re

    12/23/24 9:00:00 AM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    $UPXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Upexi Inc.

    SC 13G - UPEXI, INC. (0001775194) (Subject)

    5/31/23 7:05:10 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Upexi Inc.

    SC 13G - UPEXI, INC. (0001775194) (Subject)

    3/10/23 4:37:37 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Upexi Inc. (Amendment)

    SC 13G/A - UPEXI, INC. (0001775194) (Subject)

    3/10/23 4:36:56 PM ET
    $UPXI
    Medicinal Chemicals and Botanical Products
    Health Care